These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography. Achmad A; Hanaoka H; Yoshioka H; Yamamoto S; Tominaga H; Araki T; Ohshima Y; Oriuchi N; Endo K Cancer Sci; 2012 Mar; 103(3):600-5. PubMed ID: 22126621 [TBL] [Abstract][Full Text] [Related]
3. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685 [TBL] [Abstract][Full Text] [Related]
4. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model. Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708 [TBL] [Abstract][Full Text] [Related]
5. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer. McKnight BN; Kim S; Boerner JL; Viola NT Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603 [TBL] [Abstract][Full Text] [Related]
6. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging. Li D; Zou S; Cheng S; Song S; Wang P; Zhu X Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253 [TBL] [Abstract][Full Text] [Related]
7. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts. van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487 [TBL] [Abstract][Full Text] [Related]
8. ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer. England CG; Jiang D; Hernandez R; Sun H; Valdovinos HF; Ehlerding EB; Engle JW; Yang Y; Huang P; Cai W Mol Pharm; 2017 Oct; 14(10):3239-3247. PubMed ID: 28825843 [TBL] [Abstract][Full Text] [Related]
9. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. Niu G; Li Z; Xie J; Le QT; Chen X J Nucl Med; 2009 Jul; 50(7):1116-23. PubMed ID: 19525473 [TBL] [Abstract][Full Text] [Related]
10. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab. Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494 [TBL] [Abstract][Full Text] [Related]
11. Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET. Paudyal P; Paudyal B; Hanaoka H; Oriuchi N; Iida Y; Yoshioka H; Tominaga H; Watanabe S; Watanabe S; Ishioka NS; Endo K Cancer Sci; 2010 Apr; 101(4):1045-50. PubMed ID: 20219072 [TBL] [Abstract][Full Text] [Related]
12. The Use of PET Imaging for Prognostic Integrin α Huang CW; Hsieh WC; Hsu ST; Lin YW; Chung YH; Chang WC; Chiu H; Lin YH; Wu CP; Yen TC; Huang FT Theranostics; 2017; 7(16):4013-4028. PubMed ID: 29109795 [TBL] [Abstract][Full Text] [Related]
13. Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer. Lu X; Liu S; Han M; Yang X; Sun K; Wang H; Mu H; Du Y; Wang A; Ni L; Zhang C Int J Pharm; 2019 Apr; 560():126-135. PubMed ID: 30742982 [TBL] [Abstract][Full Text] [Related]
14. 18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts. Takeuchi S; Zhao S; Kuge Y; Zhao Y; Nishijima K; Hatano T; Shimizu Y; Kinoshita I; Tamaki N; Dosaka-Akita H Oncol Rep; 2011 Sep; 26(3):725-30. PubMed ID: 21667030 [TBL] [Abstract][Full Text] [Related]
15. Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. Eiblmaier M; Meyer LA; Watson MA; Fracasso PM; Pike LJ; Anderson CJ J Nucl Med; 2008 Sep; 49(9):1472-9. PubMed ID: 18703609 [TBL] [Abstract][Full Text] [Related]
16. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Cai W; Chen K; He L; Cao Q; Koong A; Chen X Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):850-8. PubMed ID: 17262214 [TBL] [Abstract][Full Text] [Related]
17. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534 [TBL] [Abstract][Full Text] [Related]
18. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597 [TBL] [Abstract][Full Text] [Related]
19. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. Miao Z; Ren G; Liu H; Jiang L; Cheng Z Bioconjug Chem; 2010 May; 21(5):947-54. PubMed ID: 20402512 [TBL] [Abstract][Full Text] [Related]